7.35
-0.02 (-0.27%)
| 前收盘价格 | 7.37 |
| 收盘价格 | 7.41 |
| 成交量 | 100,395 |
| 平均成交量 (3个月) | 1,297,935 |
| 市值 | 701,985,024 |
| 价格/销量 (P/S) | 606.20 |
| 股市价格/股市净资产 (P/B) | 7.12 |
| 52周波幅 | |
| 利润日期 | 14 Aug 2026 |
| 营业利益率 (TTM) | -1,621.58% |
| 稀释每股收益 (EPS TTM) | -1.39 |
| 季度收入增长率 (YOY) | -100.00% |
| 总债务/股东权益 (D/E MRQ) | 4.72% |
| 流动比率 (MRQ) | 9.08 |
| 营业现金流 (OCF TTM) | -56.39 M |
| 杠杆自由现金流 (LFCF TTM) | -30.34 M |
| 资产报酬率 (ROA TTM) | -41.77% |
| 股东权益报酬率 (ROE TTM) | -71.90% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Shattuck Labs, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.67 |
|
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 14.36% |
| 机构持股比例 | 64.06% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合